USL311
USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1].
Product Specifications
CAS Number
[1373268-67-7]
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/USL311.html
Purity
99.97
Solubility
DMSO : 18.57 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C(C1=NC(N2CCN(C3CCN(C(C)C)CC3)CCC2)=CC=C1)NC4=CC=NC=C4
Molecular Formula
C24H34N6O
Molecular Weight
422.57
Precautions
H315, H319, H320
References & Citations
[1]Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1|[2]Takacs GP, et al. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther. 2021 Jun;222:107790.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CAU36526-01 100 µL
Anti-Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) Monoclonal Antibody
Ask
View Details CAU36526-02 200 µL
Anti-Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) Monoclonal Antibody
Ask
View Details CAU36526-03 1 mL
Anti-Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) Monoclonal Antibody
Ask
View Details